FDA Approves First Treg Cell Immunotherapy for Blood Cancer Patients
The FDA has approved TREGZI, the first regulatory T cell-based immunotherapy, to improve chronic GVHD-free survival in adult blood cancer patients undergoing stem cell transplant.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day